Breakthrough Therapy: 'A Lower Bar Of Evidence'?
Executive Summary
MedPAC meeting elicits negative view of designation from one members and no one disagreed. Should US FDA reiterate what the special designation actually means?
You may also be interested in...
Gottlieb Defends Accelerated Approval, Scorns Access Limits By Payors
US FDA's accelerated approval pathway is more reliable and has better validated biomarkers than a decade ago, commissioner says, arguing coverage limits on AA products are not in the interest of public health.
The Greatest FDA Advisory Committees, Part II: The Birth Of The ‘Pazdur Moment’
With landmark advisory committee meetings coming up, we take a look back at some of the memorable panel meetings over the last 20 years. This is Part II in the series.
The Greatest US FDA Advisory Committees: A Look Back At Tumult And Turning Points
With two landmark advisory committee meetings coming up, the Pink Sheet reflects on some of the most memorable panel meetings over the last 20 years.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: